Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
- Helping Survivors of Childhood Cancer Quit Smoking
(Posted: 03/24/2009) - In this study, adult survivors of childhood cancer who smoke and want to quit will be randomly assigned to one of two quitline-based strategies: counselor-initiated quitline consultations or self-paced quitline consultations.
- Lenalidomide Maintenance Therapy for Multiple Myeloma
(Posted: 02/24/2009) - In this trial, researchers are exploring whether maintenance therapy with lenalidomide after single autologous stem cell transplantation can slow or prevent the return of multiple myeloma in patients who have undergone induction therapy.
- Enhancing Cancer Information Materials with Multimedia
(Posted: 02/10/2009) - Patients with newly diagnosed prostate or breast cancer or who are finishing or recently completed breast cancer treatment and who call the NCI's Cancer Information Service for information will be invited to participate in a trial of multimedia information during the call.
- Studying Immune System Reconstitution Following Unrelated Donor Transplantation and Graft-Versus-Host-Disease Prevention
(Posted: 01/13/2009) - Patients with high-risk, advanced hematologic malignancies will undergo induction chemotherapy, reduced-intensity immune-depleting chemotherapy, and allogeneic stem cell transplantation from a matched, unrelated donor, followed by graft-versus-host disease prevention.
- Targeted Treatment for Advanced Solid Tumors
(Posted: 12/16/2008) - This clinical trial combines the drug dasatinib with the angiogenesis inhibitor bevacizumab for patients with metastatic or unresectable solid tumors.